We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.63B
AUM Growth
-$522M
Cap. Flow
-$72.7M
Cap. Flow %
-1.1%
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$470M
2
TIL icon
Instil Bio
TIL
+$125M
3
MCRB icon
Seres Therapeutics
MCRB
+$85.1M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$84.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$83.1M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$312M
2
TGTX icon
TG Therapeutics
TGTX
+$195M
3
NVAX icon
Novavax
NVAX
+$157M
4
KROS icon
Keros Therapeutics
KROS
+$132M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$73.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
76
MoonLake Immunotherapeutics
MLTX
$1.5B
$7.15M 0.11%
700,000
– –
OBIO icon
77
Orchestra BioMed
OBIO
$253M
$6.99M 0.11%
625,000
– –
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.73M 0.1%
+90,000
New +$9.35M
VRDN icon
79
Viridian Therapeutics
VRDN
$2.28B
$5.22M 0.08%
312,328
-139,604
-31% -$2.61M
XFOR icon
80
X4 Pharmaceuticals
XFOR
$398M
$4.62M 0.07%
17,899
– –
ELVN icon
81
Enliven Therapeutics
ELVN
$4.17B
$2.1M 0.03%
62,201
– –
CEREW
82
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.01M 0.02%
233,333
– –
ADAP
83
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,499,025
Closed -$13.5M
ALEC icon
84
Alector
ALEC
$167M
– –
-1,616,879
Closed -$24.5M
ARQT icon
85
Arcutis Biotherapeutics
ARQT
$3.33B
– –
-1,165,184
Closed -$32.8M
ARVN icon
86
Arvinas
ARVN
$552M
– –
-3,672,872
Closed -$312M
CRDF icon
87
Cardiff Oncology
CRDF
$73.1M
– –
-3,290,000
Closed -$59.2M
CRNX icon
88
Crinetics Pharmaceuticals
CRNX
$8.9B
– –
-564,102
Closed -$7.96M
KROS icon
89
Keros Therapeutics
KROS
$199M
– –
-1,875,000
Closed -$132M
LEGN icon
90
Legend Biotech
LEGN
$3.74B
– –
-2,408,292
Closed -$67.8M
LYRA
91
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-16,317
Closed -$9.3M
OVID icon
92
Ovid Therapeutics
OVID
$498M
– –
-285,000
Closed -$658K
PACB icon
93
Pacific Biosciences
PACB
$435M
– –
-1,987,997
Closed -$51.6M
PASG icon
94
Passage Bio
PASG
$15.1M
– –
-16,132
Closed -$8.25M
PROF
95
Profound Medical
PROF
$293M
– –
-192,311
Closed -$3.95M
VXRT
96
DELISTED
Vaxart
VXRT
– –
-2,742,271
Closed -$15.7M
MRNS
97
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-1,300,000
Closed -$15.9M
FPRX
98
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-4,285,161
Closed -$72.9M
PAND
99
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-1,770,023
Closed -$26.3M
INBX
100
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-2,129,003
Closed -$70.2M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, RA Capital Management held 100 positions worth $6.63B, down 7.3% from $7.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RA Capital Management's Q1 2021 filing shows 18 new, 9 increased, 13 reduced and 18 closed positions. Its largest new stake was Vor Biopharma: 556,049 shares worth $479M. The largest sale was Arvinas, an estimated $312M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q1 2021 buy was Vor Biopharma: 556,049 shares worth $479M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q1 2021, an estimated $83.1M increase.
  • RA Capital Management's biggest Q1 2021 reduction was TG Therapeutics, cutting an estimated $195M.
  • RA Capital Management fully exited Arvinas in Q1 2021, selling an estimated $312M.
  • RA Capital Management's ten largest holdings make up 50% of its $6.63B portfolio in Q1 2021.
  • RA Capital Management opened 18 new positions and closed 18 in Q1 2021.
  • RA Capital Management's portfolio value fell 7.3% quarter-over-quarter to $6.63B.

Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.